Marine fungi are an important repository of bioactive molecules with great potential in different technological fields, the annual number of new compounds isolated from marine fungi is impressive and the general trend indicates that it is still on the rise. In this context, the antifungal and antimicrobial activity of the marine strain Mariannaea humicola IG100 was evaluated and two active terpenoids were isolated and characterized. Preliminary screening of activity of marine strain IG100 was carried out by agar plug diffusion methods against fungal (Penicillium griseofulvum TSF04) and bacterial (Bacillus pumilus KB66 and Escherichia coli JM109) strains. Subsequently, inhibition tests were done by using the cultural broth and the organic extract (ethyl acetate, EtOAc) by the agar well diffusion methods. The main active fractions were identified and tested for their antifungal activity against P. griseofulvum TSF04 in a 24 wells microplate at different concentrations (1000, 100, 10 and 1.0 µg/mL). Two active compounds were characterized and their relative MIC measured by the broth micro-dilution methods in a 96-well microplate against Aspergillus flavus IG133, P. griseofulvum TSF04, and Trichoderma pleuroticola IG137. Marine strain IG100 presented significant antifungal activity associated with two active compounds, the terpenoids terperstacin 1 and 19-acetyl-4-hydroxydictyodiol 2. Their MIC values were measured for A. flavus (MIC of 7.9 µg/mL and 31.3 µg/mL for 1 and 2, respectively), P. griseofulvum (MIC of 25 µg/mL and 100 µg/mL for 1 and 2, respectively) and T. pleuroticola (MIC > 500 µg/mL and 125 µg/mL for 1 and 2, respectively). They showed a rather good fungistatic effect. In this study, the first marine strain of M. humicola (IG100) was investigated for the production of bioactive molecules. Strain IG100 produced significant amounts of two bioactive terpenoids, terperstacin 1 and 19-acetyl-4-hydroxydictyodiol 2. The two compounds showed significant antifungal activities against A. flavus IG133, T. pleuroticola IG137 and P. griseofulvum TSF04. Compound 2 was identified for the first time in fungi.

中文翻译：

---

生产和从所述两个抗真菌萜类化合物的鉴定Posidonia大洋洲附生子囊菌Mariannaea腐质霉属IG100

海洋真菌是重要的生物活性分子库，在不同的技术领域都具有巨大的潜力，每年从海洋真菌中分离出的新化合物的数量令人印象深刻，并且总体趋势表明它仍在上升。在这种情况下，评估了海洋菌株Mariannaea humicola IG100的抗真菌和抗菌活性，并分离并表征了两种活性萜类化合物。通过琼脂塞扩散法对真菌菌株（Penicillium griseofulvum TSF04）和细菌菌株（短小芽孢杆菌KB66和大肠杆菌JM109）进行了海洋菌株IG100活性的初步筛选。随后，通过琼脂井扩散法使用培养液和有机提取物（乙酸乙酯，EtOAc）进行抑制测试。在24孔微孔板中以不同浓度（1000、100、10和1.0 µg / mL）鉴定出主要活性级分，并测试其对灰霉菌TSF04的抗真菌活性。对两种活性化合物进行了表征，并在96孔微孔板中通过肉汤微稀释法针对黄曲霉IG133，灰霉假单胞菌TSF04和胸膜木霉IG137对其相对MIC进行了测定。海洋菌株IG100表现出与两种活性化合物萜类萜酯1和19-乙酰基-4-羟基二苯乙烯二醇2相关的显着抗真菌活性。黄曲霉菌的MIC值进行了测量（MIC为7.9 µg / mL，31.3 µg / mL为1）。和2），灰霉菌（MIC分别为25 µg / mL和100 µg / mL，分别为MIC和500）和125 µg / mL和TP。 ）。它们显示出相当好的抑菌效果。在这项研究中，研究了人类沙门氏菌的第一个海洋菌株（IG100），用于生产生物活性分子。菌株IG100产生大量的两种生物活性萜类化合物，即萜品皂素1和19-乙酰基-4-羟基双锁二醇2。这两种化合物显示出对黄曲霉IG133，胸膜丁酸杆菌IG137和灰霉菌TSF04的显着抗真菌活性。化合物2是首次在真菌中鉴定。胸膜肺炎球菌IG137和灰绿假单胞菌TSF04。化合物2是首次在真菌中鉴定。胸膜肺炎球菌IG137和灰绿假单胞菌TSF04。化合物2是首次在真菌中鉴定。